Amersham Biosciences Collaborates with BioDiscovery Inc for CodeLink Software Development
Piscataway, NJ – January 16, 2003 – Amersham Biosciences, the life sciences business of Amersham plc (LSE: NYSE: OSE: AHM) has announced an agreement with BioDiscovery Inc. (Marina del Rey, CA) to co-develop and commercialize software for the automated analysis of Amersham Biosciences’ CodeLink™ Bioarrays. Amersham Biosciences acquired the rights to this software through the acquisition of the CodeLink™ business in July, 2002. The CodeLink System is an integrated bioarray platform capable of high performance gene expression and single nucleotide polymorphism (SNP) analysis.
Using software already developed by BioDiscovery for the CodeLink System, the agreement brings together the best of breed performance of Amersham Biosciences’ CodeLink™ bioarrays with BioDiscovery’s patented software solutions for microarrays. This combination will assist researchers in uncovering low expressing genes typically not discernible on other platforms. In addition, use of the BioDiscovery software allows seamless transition to higher density arrays when available.
“The CodeLink system provides our customers with the highest possible quality through the high sensitivity and reproducibility of our array products,” said Martin Tricarico, VP Business Development, Genomics, Amersham Biosciences. “Now, with a key software partner in BioDiscovery, we’ve also optimized the data extraction from our CodeLink arrays. This enables us to provide customers with optimal accuracy and data quality in a high throughput solution.”
“This partnership ensures that users of Amersham Biosciences’ CodeLink bioarrays will have access to image analysis software that has been specially customized to extract high quality information from CodeLink bioarrays in a high throughput, automated process”, said Greg Moore, Vice President Business Development, BioDiscovery, Inc.
Amersham Biosciences, the life sciences business of Amersham plc (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences’ products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia.
Amersham Biosciences—enabling molecular medicine
Media Contacts
| US
Eric Rayvid |
Europe
Helen Petts |
